Risk-adapted Prostate Cancer Screening Achieves Mammography-like Benefits: Evidence and Implications for Europe.
Eur Urol
2026
89
3
193-195
Dimensions of sexual self-concept and sexual dysfunctions in middle-aged men: results of the Bavarian Men's Health-Study.
Int J Impot Res
2025
Prostate-specific Membrane Antigen-radioguided Surgery in an EMBARK-like Cohort of Patients with Oligorecurrent Hormone-sensitive Prostate Cancer: Delay in Systemic Treatment.
Eur Urol Focus
2025
11
3
515-518
Cancer-related identity and advanced old age - analysis of prostate cancer survivors after radical prostatectomy over the age of 75.
BMC Geriatr
2025
25
1
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).
Future Oncol
2025
21
27
3491-3498
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.
Ann Oncol
2026
37
1
69-78
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
N Engl J Med
2025
393
24
2395-2408
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.
Ann Oncol
2025
36
7
796-806
Worry about prostate cancer and risk perception among middle-aged men: results from the PROBASE trial.
J Behav Med
2025
48
3
464-477